Shares of Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) have been given an average rating of “Reduce” by the thirteen analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating and eleven have given a hold rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $15.00.
Several analysts have issued reports on FTRE shares. William Blair reaffirmed a “market perform” rating on shares of Fortrea in a research report on Tuesday, March 4th. Evercore ISI dropped their target price on Fortrea from $20.00 to $15.00 and set an “in-line” rating on the stock in a research report on Tuesday, March 4th. Truist Financial started coverage on Fortrea in a research report on Friday, May 2nd. They set a “hold” rating and a $7.00 target price on the stock. The Goldman Sachs Group dropped their target price on Fortrea from $7.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 14th. Finally, Barclays dropped their target price on Fortrea from $6.00 to $5.00 and set an “underweight” rating on the stock in a research report on Tuesday, May 13th.
Read Our Latest Stock Report on FTRE
Institutional Trading of Fortrea
Fortrea Trading Down 6.5%
FTRE opened at $4.44 on Monday. The stock’s fifty day moving average is $6.66 and its two-hundred day moving average is $13.88. The company has a market capitalization of $401.82 million, a P/E ratio of -1.30, a PEG ratio of 1.78 and a beta of 2.15. Fortrea has a 52 week low of $4.34 and a 52 week high of $28.41. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.74.
Fortrea (NASDAQ:FTRE – Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.09. The business had revenue of $651.30 million for the quarter, compared to analysts’ expectations of $609.63 million. Fortrea had a positive return on equity of 2.00% and a negative net margin of 10.99%. Analysts forecast that Fortrea will post 0.51 earnings per share for the current year.
About Fortrea
Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Further Reading
- Five stocks we like better than Fortrea
- What is the MACD Indicator and How to Use it in Your Trading
- Nextracker’s Solar Surge: Will It Shatter Its All-Time High?
- About the Markup Calculator
- Savvy Investors Are Raising a Glass for Heineken Stock
- What is diluted earnings per share (Diluted EPS)?
- Top 4 ETFs for China Exposure After Tariff Relief
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.